Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Juan C Carril"'
Autor:
Ramón Cacabelos, Juan C Carril, Lola Corzo, Rocío Pego, Natalia Cacabelos, Margarita Alcaraz, Adriana Muñiz, Olaia Martínez-Iglesias, Vinogran Naidoo
Publikováno v:
Pharmacogenomics. 24:27-57
Anxiety and depression coexist with cognitive impairment in Alzheimer's disease along with other concomitant disorders (>60%), which require multipurpose treatments. Polypharmaceutical regimens cause drug–drug interactions and adverse drug reaction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93211d49ba4cf53e5fb36ce8ca4c5c58
https://doi.org/10.2217/pgs-2022-0137
https://doi.org/10.2217/pgs-2022-0137
Autor:
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, Lola Corzo, Natalia Cacabelos, Rocío Pego, Juan C. Carril
Publikováno v:
Life, Vol 12, Iss 3, p 460 (2022)
Alzheimer’s disease (AD) is a priority health problem with a high cost to society and a large consumption of medical and social resources. The management of AD patients is complex and multidisciplinary. Over 90% of patients suffer from concomitant
Externí odkaz:
https://doaj.org/article/4857e8b2184348ddb68d2a0e563cf036
Autor:
Ramón Cacabelos, Juan C. Carril, Lola Corzo, Lucía Fernández-Novoa, Rocío Pego, Natalia Cacabelos, Pablo Cacabelos, Margarita Alcaraz, Iván Tellado, Vinogran Naidoo
Publikováno v:
Pharmaceuticals, Vol 14, Iss 4, p 366 (2021)
Background: Mood disorders represent a risk factor for dementia and are present in over 60% of cases with Alzheimer’s disease (AD). More than 80% variability in drug pharmacokinetics and pharmacodynamics is associated with pharmacogenetics. Methods
Externí odkaz:
https://doaj.org/article/7665d2b79dba451cba8d85d380b97617
Autor:
Ramón, Cacabelos, Vinogran, Naidoo, Olaia, Martínez-Iglesias, Lola, Corzo, Natalia, Cacabelos, Rocío, Pego, Juan C, Carril
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2547
Alzheimer's disease (AD) is a priority health problem in developed countries with a high cost to society. Approximately 20% of direct costs are associated with pharmacological treatment. Over 90% of patients require multifactorial treatments, with ri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1c333d829d0ec2cb32a652e3ca76f6e0
https://pubmed.ncbi.nlm.nih.gov/36068470
https://pubmed.ncbi.nlm.nih.gov/36068470
Autor:
Ramón Cacabelos, Iván Carrera, Natalia Cacabelos, Lola Corzo, Juan C. Carril, Vinogran Naidoo, Ramón Alejo, Olaia Martínez-Iglesias, Susana Rodríguez
Publikováno v:
Current Pharmacogenomics and Personalized Medicine. 17:159-171
Background: Neurodegenerative disorders are one of the major health problems in Western countries. Genetic and epigenetic mechanisms play crucial roles in the origin and progression of these disorders. DNA methylation is the most widely studied epige
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f8ce68a222c9dfb89d5a2d82b2f0761
https://doi.org/10.2174/1875692117999201231152800
https://doi.org/10.2174/1875692117999201231152800
Autor:
Ramón Cacabelos, Juan C. Carril, Vinogran Naidoo, Natalia Cacabelos, Gjumrakch Aliev, Iván Carrera, Olaia Martínez
Publikováno v:
Drug Development Research. 82:695-706
Atremorine is a potent dopamine (DA) enhancer obtained by nondenaturing biotechnological processes from a genetic species of Vicia faba. Atremorine affects the neuronal dopaminergic system by acting as a neuroprotective agent against Parkinson's dise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78fda06ce6b87994b39f7589003e3896
https://doi.org/10.1002/ddr.21784
https://doi.org/10.1002/ddr.21784
Autor:
Ramón Cacabelos, Juan C. Carril, Marcos Santiago, Joaquin Guerra, Margarita Alcaraz, Lola Corzo
Publikováno v:
Current Pharmacogenomics and Personalized Medicine. 17:114-124
Background: Polymorphisms of selected inflammatory and metabolic genes have been described in the etiology of chronic rhinosinusitis, and these effects can be explained on a pharmacogenetic basis. Objective: The purpose of this study was to examine w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccad44b6cd18499c7b66b4b0b2c53ba1
https://doi.org/10.2174/1875692117999200801024849
https://doi.org/10.2174/1875692117999200801024849
Autor:
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, Lola Corzo, Natalia Cacabelos, Rocío Pego, Juan C. Carril
Publikováno v:
Methods in Molecular Biology ISBN: 9781071625729
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b96d5111ef00e8ae793dc41713a6bf7
https://doi.org/10.1007/978-1-0716-2573-6_13
https://doi.org/10.1007/978-1-0716-2573-6_13
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 22, Iss 13302, p 13302 (2021)
International Journal of Molecular Sciences, Vol 22, Iss 13302, p 13302 (2021)
Adverse drug reactions (ADRs) rank as one of the top 10 leading causes of death and illness in developed countries. ADRs show differential features depending upon genotype, age, sex, race, pathology, drug category, route of administration, and drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2209563912176c947db8394beb4bb12a
https://pubmed.ncbi.nlm.nih.gov/34948113
https://pubmed.ncbi.nlm.nih.gov/34948113
Publikováno v:
Expert Review of Clinical Pharmacology. 12:407-442
Adverse drug reactions (ADRs) are a major health concern worldwide. There are multiple causes of ADRs, some of which are preventable. Pharmacogenomics accounts for ≈80% variability in drug efficacy and safety. Over 400 genes are clinically relevant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6977d09f4ccbf04237dc3799cca0be36
https://doi.org/10.1080/17512433.2019.1597706
https://doi.org/10.1080/17512433.2019.1597706